Could a blood pressure drug prevent kidney failure in liver patients?

NCT ID NCT07422948

Not yet recruiting Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether starting midodrine early can help control ascites (fluid buildup in the belly) and prevent kidney problems in people with acute-on-chronic liver failure. About 113 participants will receive either midodrine plus standard care or standard care alone. The main goal is to see if more patients are free of ascites after 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: midodrine
What this could lead to: If it works, this could offer a new way to manage fluid buildup and reduce kidney complications in liver failure patients.
What could go wrong: This is a small, early-stage trial that hasn't started yet. Midodrine may not improve outcomes and could cause side effects like high blood pressure or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE-ON-CHRONIC LIVER FAILURE

Contacts and locations

Locations

Institute of Liver and Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.